Intoxicating Cannabis Products in Vape Shops: United States, 2023.

IF 4.3 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL American Journal of Preventive Medicine Pub Date : 2024-07-11 DOI:10.1016/j.amepre.2024.07.001
Matthew E Rossheim, Cassidy R LoParco, Kayla K Tillett, Ryan D Treffers, Melvin D Livingston, Carla J Berg
{"title":"Intoxicating Cannabis Products in Vape Shops: United States, 2023.","authors":"Matthew E Rossheim, Cassidy R LoParco, Kayla K Tillett, Ryan D Treffers, Melvin D Livingston, Carla J Berg","doi":"10.1016/j.amepre.2024.07.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Since 2020, many types of intoxicating cannabis products have entered the U.S. market. Hemp-derived intoxicating cannabis products, including hexahydrocannabinol and delta-8 tetrahydrocannabinol, pose concerns regarding their youth-oriented marketing, potency, and health effects. Some states have attempted to ban, restrict, or regulate their sale. However, the effectiveness of these laws and their enforcement is unclear. This study provides insights into the retail landscape of intoxicating cannabis products sold across the U.S.</p><p><strong>Methods: </strong>In November-December 2023, researchers systematically identified, called, and completed brief surveys with 520 U.S. vape shops: (n=10 per state, n=10 in District of Columbia, n=10 in Puerto Rico). The survey assessed the availability of 6 commonly sold intoxicating cannabis products. Data were analyzed by regulatory context. Analyses were conducted in 2024.</p><p><strong>Results: </strong>A total of 74% of vape shops sold any intoxicating cannabis products. Intoxicating cannabis products were sold in 43% of shops in states with delta-8 tetrahydrocannabinol bans, 53% in states with substantial regulations (intended to support safe use), 90% in states with significant restrictions (intended to limit potency/availability), and 92% in states with limited/no regulations. Intoxicating cannabis products were sold in vape shops in each state except Washington and Alaska, both of which banned hemp-derived intoxicating cannabis products and had active retail of legalized nonmedical cannabis.</p><p><strong>Conclusions: </strong>Taking licensed dispensaries into consideration, intoxicating cannabis products can be purchased in retail stores located in all 50 states; Washington, District of Columbia; and Puerto Rico. Intoxicating cannabis products are widely available in vape shops, even in most states with relevant bans/restrictions. Enhanced laws, surveillance, and enforcement are needed. The 2024 Farm Bill and state laws should explicitly prohibit hemp-derived intoxicating cannabis products.</p>","PeriodicalId":50805,"journal":{"name":"American Journal of Preventive Medicine","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Preventive Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amepre.2024.07.001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Since 2020, many types of intoxicating cannabis products have entered the U.S. market. Hemp-derived intoxicating cannabis products, including hexahydrocannabinol and delta-8 tetrahydrocannabinol, pose concerns regarding their youth-oriented marketing, potency, and health effects. Some states have attempted to ban, restrict, or regulate their sale. However, the effectiveness of these laws and their enforcement is unclear. This study provides insights into the retail landscape of intoxicating cannabis products sold across the U.S.

Methods: In November-December 2023, researchers systematically identified, called, and completed brief surveys with 520 U.S. vape shops: (n=10 per state, n=10 in District of Columbia, n=10 in Puerto Rico). The survey assessed the availability of 6 commonly sold intoxicating cannabis products. Data were analyzed by regulatory context. Analyses were conducted in 2024.

Results: A total of 74% of vape shops sold any intoxicating cannabis products. Intoxicating cannabis products were sold in 43% of shops in states with delta-8 tetrahydrocannabinol bans, 53% in states with substantial regulations (intended to support safe use), 90% in states with significant restrictions (intended to limit potency/availability), and 92% in states with limited/no regulations. Intoxicating cannabis products were sold in vape shops in each state except Washington and Alaska, both of which banned hemp-derived intoxicating cannabis products and had active retail of legalized nonmedical cannabis.

Conclusions: Taking licensed dispensaries into consideration, intoxicating cannabis products can be purchased in retail stores located in all 50 states; Washington, District of Columbia; and Puerto Rico. Intoxicating cannabis products are widely available in vape shops, even in most states with relevant bans/restrictions. Enhanced laws, surveillance, and enforcement are needed. The 2024 Farm Bill and state laws should explicitly prohibit hemp-derived intoxicating cannabis products.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Vape 商店中的有毒大麻产品:美国,2023 年。
导言:自 2020 年以来,多种类型的醉人大麻产品 (ICP) 进入了美国市场。大麻衍生的 ICP(包括六氢大麻酚 (HHC) 和δ-8 四氢大麻酚 (THC))因其面向年轻人的营销、药效和对健康的影响而备受关注。一些州已尝试禁止、限制或监管其销售。然而,这些法律的有效性及其执行情况尚不明确。目前的研究为了解全美 ICPs 的零售情况提供了参考:2023 年 11 月至 12 月,研究人员系统地确定、召集并完成了对美国 520 家汽水店的简短调查:(每个州 10 家,哥伦比亚特区 10 家,波多黎各 10 家)。调查评估了 6 种常用 ICP 的供应情况。数据按监管环境进行分析。分析于 2024 年进行:74%的汽水店出售任何 ICPs。在禁止使用δ-8四氢大麻酚的州,43%的商店出售 ICPs;在有严格规定(旨在支持安全使用)的州,53%的商店出售 ICPs;在有严格限制(旨在限制药效/可用性)的州,90%的商店出售 ICPs;在有限制/无规定的州,92%的商店出售 ICPs。除华盛顿州和阿拉斯加州外,其他各州的吸食店都出售 ICP,这两个州都禁止大麻衍生 ICP,并积极零售合法化的非医用大麻:考虑到持证药房的情况,所有 50 个州、华盛顿特区和波多黎各的零售店都可以购买到 ICP。即使在大多数有相关禁令/限制的州,也可以在汽疗店广泛购买到 ICP。需要加强法律、监督和执法。2024 年农业法案》和各州法律应明确禁止大麻衍生的 ICP。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American Journal of Preventive Medicine
American Journal of Preventive Medicine 医学-公共卫生、环境卫生与职业卫生
CiteScore
8.60
自引率
1.80%
发文量
395
审稿时长
32 days
期刊介绍: The American Journal of Preventive Medicine is the official journal of the American College of Preventive Medicine and the Association for Prevention Teaching and Research. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. Of particular emphasis are papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women''s health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and substance use disorders. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. Papers on health services research pertinent to prevention and public health are also published. The journal also publishes official policy statements from the two co-sponsoring organizations, review articles, media reviews, and editorials. Finally, the journal periodically publishes supplements and special theme issues devoted to areas of current interest to the prevention community.
期刊最新文献
Chronic Opioid Use Following Implementation of Oregon's Medicaid Back Pain Policy. Clinician response to the 2021 USPSTF recommendation for colorectal cancer screening in average risk adults aged 45-49 years. Cost-effectiveness of mandating calorie labels on prepared foods in supermarkets. Disparities in tobacco smoking and risk of cardiovascular disease in people with low socioeconomic status or serious psychological distress: A simulation analysis. Factors associated with mental healthcare utilization among United States military personnel with posttraumatic stress disorder or depression symptoms.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1